• The primary objective is the rate of progression free survival (PFS) at 24 months [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  

• Biochemical (PSA) progression free survival over time and the proportion progression free (bPFS proportion) at 2 and 3 years. bPFS is identical to PFS but includes only PSA-based endpoints or death. [ Time Frame: 2 and 3 years ] [ Designated as safety issue: No ]
  
• Local recurrence will be defined as men with locally recurrent disease confirmed pathologically within the radiation field, and will be estimated at 2 and 3 years. [ Time Frame: 2 and 3 years ] [ Designated as safety issue: No ]
  
• Metastasis-free survival (MFS) rates at 2 and 3 years. Metastasis-free survival will be defined as the date of registration to date of evidence of systemic disease on bone scan or cross sectional imaging or death, which occurs first. [ Time Frame: 2 and 3 years ] [ Designated as safety issue: No ]
  
• Safety, feasibility, and tolerability as assessed by NCI Common Toxicity Scales (v3.0), quality of life (EPIC survey), and achievement of accrual goals. [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  
• Comparison of RNA expression profile from original prostate radical prostatectomy specimen among those with PSA relapse at 2 and 3 years as compared to those without PSA relapse at the primary endpoint. [ Time Frame: 2 and 3 years ] [ Designated as safety issue: No ]
  

Drug: Docetaxel
Docetaxel 70 mg/m2 day 1 every 3 weeks for 4 cycles with prednisone 5 mg orally twice daily
Drug: Sunitinib
Sunitinib 37.5 mg orally once daily for 14 days followed by 7 days off, for 4 cycles, concurrent with docetaxel and prednisone
Radiation: EBXRT
External beam radiotherapy to the prostate bed, started on day 100, after completion of chemotherapy. 66 Gy over 6-7 weeks.

In many common malignancies such as breast cancer, trimodality therapy represents the standard-of-care approach, including initial surgical resection followed by systemic chemotherapy followed by radiotherapy for optimal local control, and targeted hormonal or biologic therapy for a period of time to reduce the ongoing risk of systemic disease recurrence. These approaches have reduced recurrence rates and improved overall survival in the adjuvant setting in breast cancer; however, the treatment of men with PSA recurrence following radical prostatectomy has generally been unsatisfying, given the high rates of persistent or recurrent disease despite salvage radiotherapy.

The primary purpose of the study is to determine the rate of biochemical (PSA) progression free survival (bPFS) in men with PSA recurrent non-metastatic prostate cancer following radical prostatectomy, who receive multimodality therapy consisting of local salvage external beam radiotherapy and systemic docetaxel-based chemotherapy plus the targeted anti-VEGF biologic therapy sunitinib. Biochemical PFS will be defined as the proportion of subjects at 24 months, post-registration, with one of the following: 1) a serum PSA value of 0.2 ng/ml or more above the post-radiotherapy PSA nadir and confirmed 4 weeks later by a second PSA measurement that was higher than the first by any amount, 2) a continued rise in the PSA level following study treatment if no nadir is experienced, defined as 2 rising values greater than the baseline PSA and separated by at least 4 weeks, 3) evidence of clinical progression or initiation of systemic therapy for progressive disease, or 4) death. Secondary objectives include finding the rate of biochemical (PSA) disease free survival over time, Two-, three-, five-, and six- year risk of local recurrence (proportion), two-, three-, five-, and six-year risk of metastases and metastasis-free survival, two-, three-, five-, and six-year risk of metastases and metastasis-free survival, Safety, feasibility, and tolerability as assessed by NCI Common Toxicity Scales (v3.0), quality of life questionnaire (EPIC-short form surveys), achievement of accrual goals. Finally, a comparison of RNA expression profiles from original prostate radical prostatectomy specimen among those with PSA relapse at 2 and 5 years as compared to those without PSA relapse at the primary endpoint.